Welcome to our dedicated page for Dbv Technologies S A SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DBV Technologies S.A. (DBVT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, with AI-powered tools to help interpret key information. DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin epicutaneous immunotherapy (EPIT) patches for food allergies and other immunologic conditions, and its filings offer detailed insight into this development activity.
Through Forms 8-K, DBV Technologies reports material events such as clinical milestones, financial results, equity offerings, and changes in corporate governance. Examples include announcements of positive topline results from the Phase 3 VITESSE trial of the Viaskin Peanut patch in peanut-allergic children aged 4 to 7 years, quarterly financial results, establishment of an at-the-market ADS offering program, and appointments or resignations of directors and senior leaders.
On this page, users can review filings related to results of operations and financial condition, other events, and board and executive changes, as disclosed under specific SEC items. For a Nasdaq-listed biopharmaceutical company like DBV Technologies, these documents help explain the status of its clinical programs, capital-raising activities, and governance structure.
Stock Titan enhances these filings with AI-generated summaries that highlight the main points of lengthy documents, helping readers quickly understand the significance of each report. Real-time updates from the EDGAR system ensure that new DBV Technologies filings, including future 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, appear promptly as they are published. Users can also monitor disclosures that may relate to executive compensation, equity issuance, or other regulatory matters connected to the company’s Viaskin-based food allergy programs.
DBV Technologies S.A. filed a proxy statement for its 2026 Annual Combined General Meeting to be held on June 3, 2026 in Châtillon, France and webcast live. The letter from management highlights positive topline results from the Phase 3 VITESSE trial of the VIASKIN® Peanut Patch in children 4–7 and plans to submit a Biologics License Application in the United States in the first half of 2026. Management reports initiation and progress on supplemental pediatric trials including COMFORT Toddlers and THRIVE in infants. The company raised $386.2 million between March 2025 and January 2026 and states this funding supports operations into the second quarter of 2027. Proxy materials, the 2025 Form 10-K, meeting agenda (40 proposals), board slate and governance materials will be mailed to ADS and ordinary shareholders in May 2026.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.
DBV Technologies S.A. reported a larger net loss as it ramps up development and commercial preparation for its Viaskin Peanut patch. For the three months ended March 31, 2026, net loss widened to $47.6 million from $27.1 million a year earlier, driven by a sharp increase in operating expenses.
Research and development spending rose to $33.4 million, sales and marketing to $4.8 million, and general and administrative costs to $10.5 million, reflecting expanded clinical activity, pre-commercial inventory build, and build‑out of U.S. commercial and corporate infrastructure. There was still no product revenue; operating income of $0.9 million came mainly from the French research tax credit.
Following a 2025 PIPE financing and warrant exercises, DBV ended the quarter with $229.2 million in cash and cash equivalents, up from $194.2 million at year‑end 2025. Management estimates this cash should fund operations into the second quarter of 2027, assuming current plans focused on Viaskin Peanut, although faster spending or new programs could shorten that runway.
DBV Technologies S.A. files an amended annual report to add detailed Part III disclosures on governance, executive compensation, ownership and related-party transactions. The filing describes a 10‑member board with nine directors independent under Nasdaq rules and gender balance requirements under French law.
As of April 15, 2026, DBV had 296,042,447 ordinary shares outstanding and a public float valued at $250.9 million as of June 30, 2025. The company reports 2025 CEO compensation of $3.36 million, including salary, bonus and equity awards, and outlines its performance‑based pay philosophy and severance terms.
The document also details equity plans with 17.8 million awards outstanding and 17.7 million shares available, large April 2025 PIPE financing generating $125.5 million plus $195.2 million from January 2026 warrant exercises, and the holdings of major shareholders such as Baker Bros., Suvretta, MPM BioImpact and Janus.
DBV Technologies S.A. director Philina Lee filed an initial Form 3, which is a required statement of her beneficial ownership as an insider of the company. The filing shows no reportable transactions in the company’s securities at this time.
DBV Technologies reported full-year 2025 results showing continued investment ahead of a potential launch of its VIASKIN® Peanut Patch. Under U.S. GAAP, operating income was $5.6 million for the year ended December 31, 2025, up from $4.2 million in 2024, mainly from higher French research tax credits.
Research and development expenses rose to $116.7 million, while general and administrative expenses increased to $32.8 million, reflecting clinical progress and launch preparation. Net loss widened to $147.0 million versus $113.9 million in 2024, though net loss per share improved to $1.05 from $1.17. Including $94 million of warrant-related proceeds received in January 2026, management expects existing cash and cash equivalents to fund operations into the second quarter of 2027, based on current plans focused on the VIASKIN Peanut Patch.
DBV Technologies reported full-year 2025 results showing continued investment ahead of a potential launch of its VIASKIN® Peanut Patch. Under U.S. GAAP, operating income was $5.6 million for the year ended December 31, 2025, up from $4.2 million in 2024, mainly from higher French research tax credits.
Research and development expenses rose to $116.7 million, while general and administrative expenses increased to $32.8 million, reflecting clinical progress and launch preparation. Net loss widened to $147.0 million versus $113.9 million in 2024, though net loss per share improved to $1.05 from $1.17. Including $94 million of warrant-related proceeds received in January 2026, management expects existing cash and cash equivalents to fund operations into the second quarter of 2027, based on current plans focused on the VIASKIN Peanut Patch.
DBV Technologies S.A. is a late-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform for food allergies, led by Viaskin Peanut. The patch delivers tiny doses of allergen through intact skin to Langerhans cells, aiming to desensitize patients while limiting systemic exposure.
Viaskin Peanut has shown positive Phase 3 results in toddlers (EPITOPE/EPOPEX) and children 4–7 years (VITESSE), with statistically significant increases in tolerated peanut dose and mainly local skin reactions. The company plans Biologics License Application submissions in the first and second half of 2026 for children 4–7 and 1–3 years old, including an FDA Accelerated Approval pathway for toddlers supported by the COMFORT Toddlers safety study.
DBV also pursues Viaskin Milk and earlier programs, but depends heavily on Viaskin Peanut. It reports a history of significant losses, potential future funding needs, extensive clinical and regulatory risk, manufacturing reliance on partners such as Sanofi and Fareva, intellectual property dependencies, and the risk of failing to maintain Nasdaq listing standards.
DBV Technologies S.A. is a late-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform for food allergies, led by Viaskin Peanut. The patch delivers tiny doses of allergen through intact skin to Langerhans cells, aiming to desensitize patients while limiting systemic exposure.
Viaskin Peanut has shown positive Phase 3 results in toddlers (EPITOPE/EPOPEX) and children 4–7 years (VITESSE), with statistically significant increases in tolerated peanut dose and mainly local skin reactions. The company plans Biologics License Application submissions in the first and second half of 2026 for children 4–7 and 1–3 years old, including an FDA Accelerated Approval pathway for toddlers supported by the COMFORT Toddlers safety study.
DBV also pursues Viaskin Milk and earlier programs, but depends heavily on Viaskin Peanut. It reports a history of significant losses, potential future funding needs, extensive clinical and regulatory risk, manufacturing reliance on partners such as Sanofi and Fareva, intellectual property dependencies, and the risk of failing to maintain Nasdaq listing standards.
DBV Technologies filed a report highlighting additional positive data from its successful Phase 3 VITESSE study of the VIASKIN® Peanut Patch in peanut-allergic children aged 4 to 7 years.
The trial met its primary endpoint, with 46.6% of children on VIASKIN Peanut classified as responders at 12 months versus 14.8% on placebo, a 31.8% difference in response rates (95% CI 24.5–39.0%, p<0.001). The company states these data support a planned Biologics License Application submission to the FDA in the first half of the year.
DBV Technologies S.A. received an updated ownership report from a group of Venrock Healthcare-related funds and individuals, including VHCP II, VHCP III, VHCP EG, associated co-investment vehicles, management LLCs, and investors Nimish Shah and Bong Y. Koh. As of December 31, 2025, each reporting person discloses 0 ordinary shares beneficially owned, representing 0.0% of the class, with no sole or shared voting or dispositive power. They also certify the securities were not acquired or held to change or influence control of DBV Technologies.
DBV Technologies S.A. received an updated ownership report from a group of Citadel-affiliated entities and Kenneth Griffin on its ordinary shares. The filing states that Mr. Griffin may be deemed to beneficially own 8,146,510 shares, representing 3.5% of the company’s outstanding shares as of December 31, 2025.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 7,413,959 shares, or 3.1% of the class, while various Citadel Securities entities report smaller positions. All reported voting and dispositive powers are shared rather than sole. The reporting group certifies the holdings are not intended to change or influence control of DBV Technologies.